Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors
Yen‐Wen Chen, David Anderson, Christopher D. Pericone, et al.
Journal of health economics and outcomes research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 9

Showing 9 citing articles:

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Alexa Zhao, Rustin D. Crutchley, Rakesh Guduru, et al.
Retrovirology (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 63
Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
Maria Mazzitelli, Lolita Sasset, Samuele Gardin, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1740-1740
Open Access | Times Cited: 11
Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis
Germán Valenzuela-Rodríguez, Carlos Díaz-Arocutipa, Jaime A. Collins, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 11, pp. 3644-3644
Open Access | Times Cited: 9
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
Emma G. Foster, Howard E. Gendelman, Aditya N. Bade
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1533-1533
Open Access | Times Cited: 13
Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy
Grace A. McComsey, Bruno Émond, Aditi Shah, et al.
Infectious Diseases and Therapy (2022) Vol. 11, Iss. 5, pp. 1883-1899
Open Access | Times Cited: 12
Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men
Jolie Hutchinson, B. Neesgard, Justyna D. Kowalska, et al.
HIV Medicine (2024) Vol. 25, Iss. 9, pp. 1058-1074
Closed Access | Times Cited: 1
Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
Prina Donga, Bruno Émond, Carmine Rossi, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 579-591
Open Access | Times Cited: 3
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
Prina Donga, Bruno Émond, Aditi Shah, et al.
Journal of Comparative Effectiveness Research (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Re-evaluating the relationship between youth with HIV and BMI in an age of increasing rates of overweight and obese youth
Samantha V. Hill, Jiaying Hao, Mia Newlin-Bradner, et al.
BMC Research Notes (2024) Vol. 17, Iss. 1
Open Access
Page 1

Scroll to top